<DOC>
	<DOCNO>NCT01204671</DOCNO>
	<brief_summary>This study design assess safety immunogenicity GSK Biologicals ' investigational vaccine GSK2321138A adults 18 year old old . This study also design assess lot-to-lot consistency vaccine GSK2321138A . The blind double blind group except GSK2604409A Group open .</brief_summary>
	<brief_title>Safety Immunogenicity Study GSK Biologicals ' Seasonal Influenza Candidate Vaccine ( GSK2321138A )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 18 year age old time first vaccination Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Healthy subject chronic wellcontrolled disease establish physical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative urine pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine plan use study period . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Administration influenza vaccine 6 month precede entry study . Planned administration / administration vaccine foreseen study protocol within 30 day vaccination Day 21 . Any contraindication intramuscular administration influenza vaccine . History hypersensitivity/anaphylaxis previous dose influenza vaccine , history reaction hypersensitivity likely exacerbate component vaccine . Any administration longacting immunemodifying drug within 3 month study start , plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease and/or fever time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . History GuillainBarr√© syndrome within 6 week receipt prior inactivate influenza virus vaccine . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . History chronic alcohol consumption and/or drug abuse . Any condition , opinion investigator , prevents subject participate study Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>GSK Biologicals influenza vaccine GSK2321138A</keyword>
</DOC>